Risk factor
Low price volatility
Profitability factor
Very strong margins and returns
About
Sanofi India Limited is a pharmaceutical firm engaged in the production and distribution of medicinal products across India, Singapore, and international markets. Its extensive product portfolio covers a wide range of therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, anti-infectives, epilepsy, and allergies. The company also offers essential vitamins, antihistamines, minerals, and other supplements, marketed under well-known brands such as Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil, reaching consumers through a network of independent distributors. Beyond its domestic and regional sales, Sanofi India Limited also exports its pharmaceutical offerings. Established in 1956, the company was initially known as Aventis Pharma Limited before adopting its current name, Sanofi India Limited, in May 2012. It is headquartered in Mumbai, India, and functions as a subsidiary of Hoechst GmbH.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of SANOFI.NS is 4281 and suggests 35% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i